Home / IFN-gamma / Human IFN-gamma ELISpot Kit

Human IFN-gamma ELISpot Kit

Catalog #: EL285
28 Citations 11 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
XEL285
PEL285
EL285
Best Seller
R&D Systems ELISpot and FluoroSpot Kits
1 Image
Product Details
Citations (28)
FAQs
Supplemental Products
Reviews (11)
Summary Product Datasheets Preparation and Storage Background

Human IFN-gamma ELISpot Kit Summary

Assay Type
Quantitative Sandwich ELISA
Format
96-well PVDF-backed microplate
Assay Length
3 hours 15 mins to 4 hours 30 mins*
Sample Type
Whole Cells
Specificity
Please see the product datasheet

* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

PRODUCT SUMMARY
ELISpot kits are highly sensitive, microplate-based assays for the detection of cytokine secreting cells. This kit is designed for the detection and enumeration of human IFN-gamma. Complete ELISpot kits are ready-to-run and require no assay development or refinement.

This ELISpot assay employs a capture antibody specific for human IFN-gamma, pre-coated onto a PVDF-backed microplate. Appropriately stimulated cells are pipetted directly into the wells and the immobilized antibody in the immediate vicinity of the secreting cells binds secreted human IFN-gamma. Following wash steps and incubation with a biotinylated detection antibody, alkaline-phosphatase conjugated to streptavidin is added. Unbound enzyme is subsequently removed by washing and a substrate solution (BCIP/NBT) is added. A blue-black colored precipitate forms at the sites of cytokine localization and appears as spots, with each individual spot representing an individual human IFN-gamma secreting cell. The spots can be counted with an automated ELISpot reader system or manually using a stereomicroscope.

PRODUCT FEATURES

  • Detect and quantitate individual cells secreting human IFN-gamma
  • High sensitivity - ELISpot assays can measure responses with frequencies well below 1 in 100,000 cells
  • No in vitro expansion of cells required
  • High-throughput - ELISpot assays use only a small number of primary cells

KIT CONTENTS

  • Human IFN-gamma Microplate
  • Biotinylated Detection Antibody
  • Streptavidin conjugated to Alkaline Phosphatase
  • Dilution Buffers
  • Wash Buffer Concentrate
  • BCIP/NBT Chromogen
  • Human IFN-gamma Positive Control

OTHER REAGENTS REQUIRED

  • Pipettes and pipette tips
  • Deionized or distilled water
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • 500 mL graduated cylinder
  • 37 °C CO2 incubator
  • Sterile culture media
  • Dissection microscope or an automated ELISpot reader

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Stability & Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: IFN-gamma

IFN-gamma (Interferon-gamma) is the prototype proinflammatory cytokine and is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects. In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation. IFN-gamma dimers signal through a receptor complex of two IFN-gamma R1 and two IFN-gamma R2 subunits.

Long Name:
Interferon gamma
Entrez Gene IDs:
3458 (Human); 15978 (Mouse); 25712 (Rat); 396991 (Porcine); 281237 (Bovine); 403801 (Canine); 493965 (Feline)
Alternate Names:
IFG; IFI; IFNG; IFNgamma; IFN-gamma; Immune interferon; interferon gamma; interferon, gamma
⚠ WARNING: This product can expose you to chemicals including methanol, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information, go to www.P65Warnings.ca.gov.

Citations for Human IFN-gamma ELISpot Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

28 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
    Authors: Vos, JL;Burman, B;Jain, S;Fitzgerald, CWR;Sherman, EJ;Dunn, LA;Fetten, JV;Michel, LS;Kriplani, A;Ng, KK;Eng, J;Tchekmedyian, V;Haque, S;Katabi, N;Kuo, F;Han, CY;Nadeem, Z;Yang, W;Makarov, V;Srivastava, RM;Ostrovnaya, I;Prasad, M;Zuur, CL;Riaz, N;Pfister, DG;Klebanoff, CA;Chan, TA;Ho, AL;Morris, LGT;
    Nature medicine
    Species: Human
    Sample Types: Whole Cells
  2. Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition
    Authors: F Mai, J Volzke, EC Reisinger, B Müller-Hil
    Vaccines, 2022-09-19;10(9):.
    Species: Human
    Sample Types: Whole Cells
  3. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort
    Authors: D Menges, KD Zens, T Ballouz, N Caduff, D Llanas-Cor, HE Aschmann, A Domenghino, C Pellaton, M Perreau, C Fenwick, G Pantaleo, CR Kahlert, C Münz, MA Puhan, JS Fehr
    Nature Communications, 2022-08-18;13(1):4855.
    Species: Human
    Sample Types: Whole Cells
  4. Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2
    Authors: B Müller-Hil, F Mai, M Müller, J Volzke, EC Reisinger
    Vaccines, 2022-02-17;10(2):.
    Species: Human
    Sample Types: Whole Cells
  5. FcgammaR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity
    Authors: V Mysore, X Cullere, J Mears, F Rosetti, K Okubo, PX Liew, F Zhang, I Madera-Sal, F Rosenbauer, RM Stone, JC Aster, UH von Andria, AH Lichtman, S Raychaudhu, TN Mayadas
    Nature Communications, 2021-08-09;12(1):4791.
    Species: Human
    Sample Types: Whole Cell
  6. Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART
    Authors: A Tripiciano, O Picconi, S Moretti, C Sgadari, A Cafaro, V Francavill, A Arancio, G Paniccia, M Campagna, MR Pavone-Cos, L Sighinolfi, A Latini, VS Mercurio, MD Pietro, F Castelli, A Saracino, C Mussini, GD Perri, M Galli, S Nozza, F Ensoli, P Monini, B Ensoli
    EBioMedicine, 2021-04-07;0(0):103306.
    Species: Human
    Sample Types: Whole Cells
  7. Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis
    Authors: X Wang, D Ji, B Zhu, S Jiang, L Han, Y Wang, H Mai, S Xu, H Jiang, G Wang, Y Rong
    Microb. Pathog., 2020-01-27;0(0):104009.
    Species: Human
    Sample Types: Whole Cells
  8. The first clinical use of a recombinant Lactococcus lactis expressing human papillomavirus type 16 E7 oncogene oral vaccine: A phase I safety and immunogenicity trial in healthy women volunteers
    Authors: AH Mohseni, S Taghinezha, H Keyvani
    Mol. Cancer Ther., 2019-10-23;0(0):.
    Species: Human
    Sample Types: Whole Cells
  9. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
    Authors: S Peng, JM Zaretsky, AHC Ng, W Chour, MT Bethune, J Choi, A Hsu, E Holman, X Ding, K Guo, J Kim, AM Xu, JE Heath, WJ Noh, J Zhou, Y Su, Y Lu, J McLaughlin, D Cheng, ON Witte, D Baltimore, A Ribas, JR Heath
    Cell Rep, 2019-09-03;28(10):2728-2738.e7.
    Species: Human
    Sample Types: Whole Cells
  10. Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine
    Authors: S Taghinezha, AH Mohseni, H Keyvani, MR Razavi
    Mol Ther Methods Clin Dev, 2019-08-29;15(0):40-51.
    Species: Human
    Sample Types: Whole Cells
  11. Immunogenic neoantigens derived from gene fusions stimulate T cell responses
    Authors: W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, V Makarov, D Hoen, MG Dalin, L Wexler, R Ghossein, N Katabi, Z Nadeem, MA Cohen, SK Tian, N Robine, K Arora, H Geiger, P Agius, N Bouvier, K Huberman, K Vanness, JJ Havel, JS Sims, RM Samstein, R Mandal, J Tepe, I Ganly, AL Ho, N Riaz, RJ Wong, N Shukla, TA Chan, LGT Morris
    Nat. Med., 2019-04-22;0(0):.
    Species: Human
    Sample Types: Whole Cells
  12. A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
    Authors: YB Pang, J He, BY Cui, S Xu, XL Li, MY Wu, R Liang, Y Feng, X Guo, XH Zhang, XL Luo
    Stem Cells Int, 2019-04-01;2019(0):5680327.
    Species: Human
    Sample Types: Whole Cells
  13. Secretion of IFN-? Associated with Galectin-9 Production by Pleural Fluid Cells from a Patient with Extrapulmonary Tuberculosis
    Authors: J Zhao, B Shiratori, H Chagan-Yas, M Matsumoto, T Niki, M Tanaka, Y Takahashi, O Usami, Y Ashino, T Hattori
    Int J Mol Sci, 2017-06-28;18(7):.
    Species: Human
    Sample Types: Whole Cells
  14. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Authors: Ren J, Liu X, Fang C, Jiang S, June C, Zhao Y
    Clin Cancer Res, 2016-11-04;23(9):2255-2266.
    Species: Human
    Sample Types: Whole Cells
  15. Comparative Multi-Donor Study of IFNgamma Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays.
    Authors: Hagen J, Zimmerman R, Goetz C, Bonnevier J, Houchins J, Reagan K, Kalyuzhny A
    Cells, 2015-02-11;4(1):84-95.
    Species: Human
    Sample Types: Whole Cells
  16. Antigen-triggered interferon-gamma and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease.
    Authors: Nogueira R, Gomes-Silva A, Bittar R, Silva Mendonca D, Amato V, da Silva Mattos M, Oliveira-Neto M, Coutinho S, Da-Cruz A
    Clin Exp Immunol, 2014-09-01;177(3):679-86.
    Species: Human
    Sample Types: Whole Cells
  17. Correlations between vaccinia-specific immune responses within a cohort of armed forces members.
    Authors: Umlauf B, Ovsyannikova I, Haralambieva I, Kennedy R, Vierkant R, Pankratz V, Jacobson R, Poland G
    Viral Immunol, 2011-09-29;24(5):415-20.
    Species: Human
    Sample Types: Whole Cells
  18. Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.
    Authors: Poirier N, Haudebourg T, Brignone C, Dilek N, Hervouet J, Minault D, Coulon F, de Silly RV, Triebel F, Blancho G, Vanhove B
    Clin. Exp. Immunol., 2011-02-24;164(2):265-74.
    Species: Primate - Papio anubis (Olive Baboon)
    Sample Types: Whole Cells
  19. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms.
    Authors: Correale J, Farez M
    J. Immunol., 2009-10-07;183(9):5999-6012.
    Species: Human
    Sample Types: Whole Cells
  20. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
    Authors: Fan K, Borden E, Yi T
    J. Interferon Cytokine Res., 2009-08-01;29(8):451-60.
    Species: Human
    Sample Types: Whole Cells
  21. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.
    Authors: Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, Kumpfel T, Moldenhauer A, Rader C, Sonderegger P, Pollmann W, Tiefenthaller C, Bauer J, Lassmann H, Wekerle H, Karagogeos D, Hohlfeld R, Linington C, Meinl E
    Proc. Natl. Acad. Sci. U.S.A., 2009-04-28;106(20):8302-7.
    Species: Human
    Sample Types: Whole Cells
  22. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease.
    Authors: McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH
    J. Immunol., 2009-03-15;182(6):3892-901.
    Species: Human
    Sample Types: Whole Cells
  23. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
    Authors: Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B
    Vaccine, 2009-02-07;27(25):3306-12.
    Species: Human
    Sample Types: Whole Cells
  24. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Authors: Ysrraelit MC, Gaitan MI, Lopez AS, Correale J
    Neurology, 2008-12-09;71(24):1948-54.
    Species: Human
    Sample Types: Whole Cells
  25. Human bronchial intraepithelial T cells produce interferon-gamma and stimulate epithelial cells.
    Authors: Hirosako S, Goto E, Fujii K, Tsumori K, Hirata N, Tsumura S, Kamohara H, Kohrogi H
    Clin. Exp. Immunol., 2008-11-26;155(2):266-74.
    Species: Human
    Sample Types: Whole Cells
  26. Regulatory NK cells suppress antigen-specific T cell responses.
    Authors: Deniz G, Erten G, Kucuksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M
    J. Immunol., 2008-01-15;180(2):850-7.
    Species: Human
    Sample Types: Whole Cells
  27. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.
    Authors: Correale J, Rush C, Amengual A, Goicochea MT
    J. Neuroimmunol., 2005-05-01;162(1):173-83.
    Species: Human
    Sample Types: Whole Cells
  28. A multidonor ELISPOT study of IL-1 beta, IL-2, IL-4, IL-6, IL-13, IFN-gamma and TNF-alpha release by cryopreserved human peripheral blood mononuclear cells.
    Authors: Bailey T, Stark S, Grant A, Hartnett C, Tsang M, Kalyuzhny A
    J. Immunol. Methods, 2002-12-15;270(2):171-82.
    Species: Human
    Sample Types: Whole Cells

FAQs

No product specific FAQs exist for this product, however you may

View all ELISpot and FluoroSpot Kit FAQs
Loading...

Reviews for Human IFN-gamma ELISpot Kit

Average Rating: 4.6 (Based on 11 Reviews)

5 Star
63.64%
4 Star
36.36%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human IFN-gamma ELISpot Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human IFN-gamma ELISpot Kit
By Anonymous on 08/20/2021
Sample Tested: Human T cells
Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 03/26/2021
Sample Tested: Human T cell
Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 02/09/2021
Sample Tested: Human CD8 cells
Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 09/30/2020
Sample Tested: Activated human CD8 T cells

Works really well as compared to kits from other companies. Easy to follow protocol.

Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 07/15/2020
Sample Tested: Peripheral blood mononuclear cells (PBMCs)

The kit is easy to use and produced excellent results. Couple things that need to be added are: Information regarding storage conditions of the developed kit (spots); In my experience, the kit once developed is pretty stable and can be stored @ 4C in the dark for at least few weeks. The positive control for the kit produces a lawn rather than spots, something to keep in mind.

Human IFN-gamma ELISpot Kit
By Anonymous on 07/10/2020
Sample Tested: Peripheral blood T cells
Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 07/10/2020
Sample Tested: Human cells
Human IFN-gamma ELISpot Kit
By Anonymous on 01/25/2020
Sample Tested: Serum and Plasma
Human IFN-gamma ELISpot Kit
By Anonymous on 07/08/2019
Sample Tested: 2120Ep human embryonal carcinoma cell line,Activated Human CD8 T-cells co-cultured with Leukaemia cells

The kit is easy to use and produced excellent results. Couple things that need to be added are: Information regarding storage conditions of the developed kit (spots); In my experience, the kit once developed is pretty stable and can be stored @ 4C in the dark for at least few weeks. The positive control for the kit produces a lawn rather than spots, something to keep in mind.

Human IFN-gamma ELISpot Kit
By Anonymous on 05/14/2018
Sample Tested: Cell Culture Samples
Human IFN-gamma ELISpot Kit EL285
Human IFN-gamma ELISpot Kit
By Anonymous on 03/22/2018
Sample Tested: Human PBMC